The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure

American Journal of Medicine

Volumn 104, Issue 6, 1998, Pages 533-538

  Gottlieb, Stephen S ^a   Khatta, Meenakshi ^a   Wentworth, Derek ^a   Roffman, David ^a   Fisher, Michael L ^a   Kramer, William G ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FUROSEMIDE; LOOP DIURETIC AGENT; TORASEMIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIURESIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; EDEMA; FEMALE; HEART FAILURE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

AGED; DIURESIS; DIURETICS; FEMALE; FUROSEMIDE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SULFONAMIDES;

EID: 0032103580     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00111-9     Document Type: Article

References (18)

1. 1. Graves EJ. Detailed diagnoses and procedures, national hospital discharge survey, 1990. Vital Health Stat 13. 1992;113:1-225.
2. 2. Vasko MR, Brown-Cartwright D, Knochel JP, et al. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med. 1985;102:314-318.
3. 3. March C, Farthing D, Wells B, et al. Solid phase extraction and liquid chromatography of toresemide and metabolites from plasma and urine. J Pharm Sci. 1990;79:453-457.
4. 4. Rapaka RS, Roth J, Viswanathan C, et al. Improved method for the analysis of furosemide in plasma by high performance liquid chromatography. J Chromatogr. 1982;227:463-469.
5. 5. Gehr TWB, Rudy DW, Matzke GR, et al. The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin Pharmacol Ther. 1994;56:31-38.
6. 6. Brater DC, Siewell R, Anderson S, et al. Absorption and disposition of furosemide in congestive heart failure. Kidney Int. 1982;22:171-176.
7. 7. Chaturvedi PR, O'Donnell JP, Nicholas JM, et al. Steady state absorption kinetics and pharmacodynamics of furosemide in congestive heart failure. Int J Clin Pharm Ther Toxic. 1987;25:123-128.
8. 8. Vargo D, Kramer WG, Black PK, et al. The pharmacodynamics of torsemide in patients with congestive heart failure. Clin Pharmacol Ther. 1994;56:48-54.
9. 9. Brater DC, Leinfelder J, Anderson SA. Clinical pharmacology of torsemide, a new loop diuretic. Clin Pharmacol Ther. 1987;42:187-192.
10. 10. Dormans TP, van Meyel JJ, Gerlag PG, et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol. 1996;28:376-382.
11. 11. Andreasen F, Mikkelsen E. Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure. Euro J Clin Pharmacol. 1977;12:15-22.
12. 12. Greither A, Goldman S, Edelen JS, et al. Pharmacokinetics of furosemide in patients with congestive heart failure. Pharmacology. 1979;19:121-131.
13. 13. Brater DC, Day B, Burdette A, Anderson S. Bumetanide and furosemide in heart failure. Kid Int. 1984;26:183-189.
14. 14. Brater DC. Pharmacokinetics of loop diuretics in congestive heart failure. Br Heart J. 1994;72:S40-43.
15. 15. Rudy DW, Gehr TWB, Matzke GR, et al. The pharmacodynamics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin Pharmacol Ther. 1994;56:39-47.
16. 16. Odlind BO, Beermann B. Diuretic resistance: reduced bioavailability and effect of oral furosemide. BMJ. 1980;280:1577.
17. 17. Bayliss J, Norell M, Canepa-Anson R, et al. Untreated heart failure: clinical and neuroendocrine effect of introducing diuretics. Br Heart J. 1987;57:17-22.
18. 18. Nicholls MG, Espiner EA, Donald RA, Hughes H. Aldosterone and its regulation during diuresis in patients with gross congestive heart failure. Clin Sci Molec Med. 1974;47:301-315.